Apolipoprotein C3 and risk of cardiovascular events and death in patients on optimized statin treatment after recent acute coronary syndrome
In patients with recent ACS on optimized statins without severe hypertriglyceridemia, neither baseline ApoC3 (accounting for ApoB) nor ApoC3 change with alirocumab predicted MACE or death. It is uncertain whether targeted therapies producing larger reductions in ApoC3 from higher baseline levels will affect cardiovascular risk.
Authors
- Philippe Gabríel Steg (ORCID: https://orcid.org/0000-0001-6896-2941)
- J. Wouter Jukema (ORCID: https://orcid.org/0000-0002-3246-8359)
- Deepak L. Bhatt (ORCID: https://orcid.org/0000-0002-1278-6245)
- Christa M. Cobbaert (ORCID: https://orcid.org/0000-0003-3565-1404)
- Geneviève Garon (ORCID: https://orcid.org/0009-0001-0486-6325)
- Shaun G. Goodman (ORCID: https://orcid.org/0000-0001-8068-2440)
- Vera Bittner (ORCID: https://orcid.org/0000-0001-9456-850X)
- Esther Reijnders (ORCID: https://orcid.org/0000-0003-3520-5869)
- Harvey D. White (ORCID: https://orcid.org/0000-0001-7712-6750)
- Gregory G. Schwartz (ORCID: https://orcid.org/0000-0003-2954-0695)
- Sergio Fazio (ORCID: https://orcid.org/0000-0002-2743-9836)
- Ivana Stevanović (ORCID: https://orcid.org/0000-0002-4588-3447)
- Michael J. Szarek (ORCID: https://orcid.org/0000-0002-0046-0264)
- L. Renee Ruhaak (ORCID: https://orcid.org/0000-0003-3737-3807)
- Robert A. Harrington
Institutions
- St. Michael's Hospital (CA)
- State University of New York (US)
- University of Auckland (NZ)
- University of Alberta (CA)
- Inserm (FR)
- SUNY Downstate Health Sciences University (US)
- University of Toronto (CA)
- Institut Universitaire de France (FR)
- Regeneron (United States) (US)
- Université Paris Cité (FR)
- Cornell University (US)
- Leiden University Medical Center (NL)
- University of Alabama at Birmingham (US)
- Greenlane Clinical Centre (NZ)
- Sanofi (Spain) (ES)
- Assistance Publique – Hôpitaux de Paris (FR)
- Mount Sinai Hospital (US)
- Sanofi (Canada) (CA)
- Netherlands Heart Institute (NL)
- Canadian VIGOUR Centre (CA)
- Meridian Clinical Research (US)
- Hôpital Bichat-Claude-Bernard (FR)
- Weill Cornell Medicine (US)
- University of Colorado Denver (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- European Journal of Preventive Cardiology
- Published
- 2025-02-08
- DOI
- https://doi.org/10.1093/eurjpc/zwaf067
- Citations
- 6
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 12.04
Funders
- Sanofi
- Regeneron Pharmaceuticals